BACE1 and Cognitive impairment: Importantly, BACE1-/- mice are devoid of Aβ amyloidosis, electrophysiological dysfunctions, and cognitive deficits (192), implying targeted BACE1 inhibition to improve Aβ-mediated loss of cognitive function in humans with AD.